Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$72.56 USD
-0.95 (-1.29%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $72.58 +0.02 (0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GILD 72.56 -0.95(-1.29%)
Will GILD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GILD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
GILD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol Myers (BMY) Loses 20.5% YTD: Should You Retain or Fold?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Other News for GILD
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
UN urges Gilead to "make history" with game-changing HIV drug
Here are Big Pharma’s leading blockbuster makers
Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD)
Check Out What Whales Are Doing With GILD